About five percent of the Swedes are treated with antidepressants, mostly SSRI:s. One third of those are non-responders. In that situation augmentation with a noradrenergic drug, such as reboxetine, can be a successful treatment strategy. This paper discusses clinical and scientific experiences of combinating SSRI:s and NRI:s.